SWOG clinical trial number
CTSU/E1505

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

Closed
Phase
Published
Abbreviated Title
Phase III Adjuvant Chemo and/or Bevacizumab in NSCLC
Activated
07/01/2007
Closed
09/20/2013
Participants
CTSU

Research committees

Lung Cancer

Treatment

Cisplatin Docetaxel Gemcitabine hydrochloride Vinorelbine tartrate Bevacizumab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

C Steuer;O Jegede;S Dahlberg;H Wakelee;S Keller;W Tester;D Gandara;S Graziano;A Adjei;C Butts;S Ramalingam;J Schiller Journal of Thoracic Oncology Jun;16(6):960-967. doi: 10.1016/j.jtho.2020.12.017. Epub 2021 Feb 1.

PMid: PMID33539971 | PMC number: PMC8383783

2019

E1505: Adjuvant Chemotherapy +/- Bevacizumab for early stage NSCLC: Updated chemotherapy subset analysis

H Wakelee;SE Dahlberg;S Keller;WJ Tester;DR Gandara;S Graziano;A Adjei;N Leighl;CA Butts;S Aisner;J Rothman;J Patel;MD Sborov;S McDermott;R Perez-Soler;A Traynor;TL Evans;S Ramalingam;JH Schiller WCLC IASCLC Annual Meeting (September 7-10, 2019, Barcelona, Spain), accepted, mini-oral presentation

2017

Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): results of E1505

H Wakelee;S Dahlberg;S Keller;WJ Tester;D Gandara;S Graziano;A Adjei;N Leighl;S Aisner;J Rothman;J Patel;MD Sborov;S McDermott;R Perez-Soler;A Traynor;C Butts;T Evans;L Horn;S Ramalingam;JH Schiller Lancet Oncology Dec;18(12):1610-1623, 2017; Nov 9 [Epub ahead of print]

PMid: PMID29129443 | PMC number: PMC5789803

2016

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets

H Wakelee;S Dahlberg;S Keller;W Tester;D Gandara;S Graziano;A Adjei;N Leighl;C Butts;S Aisner;J Rothman;J Patel;M Sborov;R McDermott;R Perez-Soler;A Traynor;T Evans;L Horn;S Ramalingam;J Schiller Journal of Clinical Oncology 34, 2016 (suppl; abstr 8507); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral session

2011

Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early stage non-small cell lung cancer (NSCLC)

H Wakelee;S Dahlberg;S Keller;DR Gandara;SL Graziano;AA Adjei;JH Schiller Journal of Clinical Oncology 29:(suppl; abstr 7013)ASCO 2011 Annual Meeting, poster discussion presentation

Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer (NSCLC)

H Wakelee;S Dahlberg;S Keller;DR Gandara;S Graziano;N Leigh;A Adjei;J Schiller J Thorac Oncol. 2011; 6(6)(suppl 2): S464. abstract 042.03; IASLC, 14th World Conference on Lung Cancer, oral presentation;

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase